Alvin Shih, MD, MBA

Chief Executive Officer

Alvin has served as CEO of Enzyvant since November 2016. Prior to joining Enzyvant, Alvin was the Chief Operating Officer for Rare Diseases at Pfizer, and the global head of R&D at Retrophin. Prior to joining biopharma, he was a healthcare consultant at LEK Consulting and McKinsey & Company. Alvin has an MD from the University of Alabama, an MBA from Northwestern University, and completed his training in internal medicine at the Massachusetts General Hospital.

Alan Kimura, MD, PhD

Chief Medical Officer

Alan has served as Chief Medical Officer of Enzyvant since April of 2018. Prior to Enzyvant, he served as Chief Medical Officer for SutroVax and led clinical and regulatory strategies for rare diseases at Translate Bio. Alan has held senior clinical development, research, and medical affairs roles at Shire, Novartis, Altus, Transkaryotic Therapies, BioChem Pharma, SmithKline Beecham Biologicals, and Wyeth-Lederle Vaccines. Alan received his B.A. in Bacteriology from University of California – Berkeley, his M.A. and Ph.D. in Microbiology from University of California – Davis, and his M.D. from University of Miami School of Medicine.

Morgan Molloy

Chief Commercial Officer

Morgan has more than 25 years of broad commercial leadership experience in the biopharmaceutical industry. Prior to Enzyvant, he served as the Head of U.S. Commercial for Spark Therapeutics and was responsible for the development of commercial strategy and implementation in the U.S. for Spark’s investigational gene therapy programs. Starting in 2007, Morgan spent seven years at Sanofi-Genzyme and held multiple commercial leadership roles in several of the legacy Genzyme franchises, including the Fabry disease business. Morgan started his career at Allergan and Biogen and holds a BS in Business Management from the University of Massachusetts Lowell.

Tamara Joseph, JD, LLM

General Counsel

Tamara was named General Counsel of Enzyvant in June of 2018. She has served as General Counsel of InVivo Therapeutics, Cubist Pharmaceuticals, Mayne Pharma, and Transkaryotic Therapies. Earlier in her career, Tamara established and led the Biogen Idec legal department’s operations outside the United States, and she began her legal career at the law firms of Morrison & Foerster and Fried Frank. She has a JD from the University of Michigan Law School and LLM degrees from the College of Europe in Belgium and the University of Paris. Tamara is also an independent director at public health non-profit Heluna Health and is a member of that Board’s Executive Committee and Chair of its Governance & Nominating Committee.

Judy Chuk, PhD

VP, Strategy & Operations

Judy is responsible for ensuring operational resources for advancement of Enzyvant’s portfolio and strategic development of the business. Judy is a bench scientist by training and brings over 10 years of strategic planning, business operations, and portfolio management experience across multiple therapeutic areas in the biopharma industry. Her experience spans across many functional areas including all phases of drug discovery, development, and commercialization. Most recently, she served as COO and Head of Strategy and Operations for Pfizer’s Rare Disease Research Unit in Cambridge, MA. Judy holds a PhD from Harvard University and a BA from Rutgers University.